Alpha 2.0
Login Register
» Articles » PMID: 21690622

Use of Antistaphylococcal Beta-lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-resistant Staphylococcus Aureus: Role of Enhanced Daptomycin Binding

Overview
Journal Clin Infect Dis
Publisher Oxford University Press
Specialty Infectious Diseases
Date 2011 Jun 22
PMID 21690622
Citations 112
Authors
Abhay Dhand
Arnold S Bayer
Joseph Pogliano
Soo-Jin Yang
Michael Bolaris
Victor Nizet
Guiquing Wang
George Sakoulas
Affiliations
Soon will be listed here.
Abstract

We used daptomycin plus antistaphylococcal β-lactams (ASBL) to clear refractory MRSA bacteremia. In vitro studies showed enhanced daptomycin bactericidal activity, increased membrane daptomycin binding, and decrease in positive surface charge induced by ASBLs against daptomycin nonsusceptible MRSA. Addition of ASBLs to daptomycin may be of benefit in refractory MRSA bacteremia. (Although the official designation is "daptomycin nonsusceptiblity," we will use the term "daptomycin-resistance" in this paper for facility of presentation.).

Citing Articles

It takes two to tango: Preserving daptomycin efficacy against daptomycin-resistant MRSA using daptomycin-phage co-therapy.

Madison C, Steinert A, Luedeke C, Hajjafar N, Srivastava P, Berti A Microbiol Spectr. 2024; :e0067924.

PMID: 39470283 PMC: 11619598. DOI: 10.1128/spectrum.00679-24.

Antibiotics Trigger Host Innate Immune Response via Microbiota-Brain Communication in .

Wu Y, Li G, Tang H Int J Mol Sci. 2024; 25(16).

PMID: 39201552 PMC: 11354627. DOI: 10.3390/ijms25168866.

Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study.

Hammond J, Benigno M, Bleibdrey N, Ansari W, Nguyen J Drugs Real World Outcomes. 2024; 11(2):273-283.

PMID: 38564101 PMC: 11176132. DOI: 10.1007/s40801-024-00422-5.

New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended.

Oliva A, Cogliati Dezza F, Cancelli F, Curtolo A, Falletta A, Volpicelli L J Clin Med. 2023; 12(24).

PMID: 38137762 PMC: 10743892. DOI: 10.3390/jcm12247693.

New advances in management and treatment of cardiac implantable electronic devices infections.

Russo A, Serraino R, Serapide F, Trecarichi E, Torti C Infection. 2023; 52(2):323-336.

PMID: 37996646 PMC: 10955036. DOI: 10.1007/s15010-023-02130-8.

References
1.
Cosgrove S, Sakoulas G, Perencevich E, Schwaber M, Karchmer A, Carmeli Y . Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2002; 36(1):53-9. DOI: 10.1086/345476. View
2.
Snydman D, McDermott L, Jacobus N . Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves. J Chemother. 2006; 17(6):614-21. DOI: 10.1179/joc.2005.17.6.614. View
3.
Komatsuzawa H, Suzuki J, Sugai M, Miyake Y, Suginaka H . Effect of combination of oxacillin and non-beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1994; 33(6):1155-63. DOI: 10.1093/jac/33.6.1155. View
4.
Fowler Jr V, Olsen M, Corey G, Woods C, Cabell C, Reller L . Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003; 163(17):2066-72. DOI: 10.1001/archinte.163.17.2066. View
5.
Yang S, Xiong Y, Boyle-Vavra S, Daum R, Jones T, Bayer A . Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother. 2010; 54(8):3161-9. PMC: 2916313. DOI: 10.1128/AAC.00487-10. View